前列腺癌:關鍵意見領袖 (KOL) 的考察 - 最新趨勢簡報
Prostate Cancer: Update Bulletin [Feb 2016]
|前列腺癌:關鍵意見領袖 (KOL) 的考察 - 最新趨勢簡報 Prostate Cancer: Update Bulletin [Feb 2016]|
|出版日期: 2016年02月01日||內容資訊: 英文||
本最新趨勢簡報，調查前列腺癌的治療藥的開發相關最新的事件和關鍵意見領袖 (KOL) 對其見解的彙整。
Gain new KOL insights on the latest events with the potential to shape the targeted treatment of Prostate Cancer (PC). Topics covered include opinions about the role of custirsen (OGX-011; OncoGenex/Teva) in combination with Jevtana (cabazitaxel; Sanofi) as a second-line treatment for metastatic castrate-resistant PC (mCRPC), and the development of Lynparza (olaparib; AstraZeneca) as a treatment for BRCA1/2 or ATM gene mutated mCRPC in patients who have received prior taxane-based chemotherapy and Zytiga (abiraterone acetate; Johnson & Johnson), or Xtandi (enzalutamide; Astellas/Medivation). The UK's National Institute for Health and Clinical Excellence's (NICE) recommendations concerning the use of Xtandi and Zytiga for treating mCRPC in a pre-chemotherapy setting are also discussed.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.